


Product Data Sheet

Fostamatinib (R788)

Cat. No.:	B2284
CAS No.:	901119-35-5
Formula:	C23H26FN6O9P
M.Wt:	580.46
Synonyms:	
Target:	Tyrosine Kinase
Pathway:	Spleen Tyrosine Kinase (Syk)
Storage:	Store at -20°C



Solvent & Solubility

insoluble in H₂O; ≥100.4 mg/mL in DMSO; ≥3.05 mg/mL in EtOH with gentle warming and ultrasonic

In Vitro

	Solvent	Mass Concentration	Mass		
			1mg	5mg	10mg
Preparing Stock Solutions		1 mM	1.7228 mL	8.6139 mL	17.2277 mL
		5 mM	0.3446 mL	1.7228 mL	3.4455 mL
		10 mM	0.1723 mL	0.8614 mL	1.7228 mL

Please refer to the solubility information to select the appropriate solvent

Biological Activity

Shortsummary

Spleen tyrosine kinase (Syk) inhibitor

IC₅₀ & Target

In Vitro

Cell Viability Assay

Cell Line: Diffuse large B-cell lymphoma (DLBCL) cell lines

Preparation method: The solubility of this compound in DMSO is > 100.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reacting conditions: 4 μM, 96 h

In Vivo	Applications:	R788 was a prodrug of the active metabolite. R406 induced apoptosis of the majority of examined DLBCL cell lines. In R406-sensitive DLBCL cell lines, R406 specifically inhibited both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYK-dependent phosphorylation of the B-cell linker protein [BLNK]).
	Animal experiment	
	Animal models:	Eμ- TCL1 transgenic mouse model of CLL, B6/C3H F1 mice
	Dosage form:	Intraperitoneal administration, 18 consecutive days at a daily dose of 80 mg/kg
	Applications:	R788 (80 mg/kg/d) inhibited the growth of adoptively transferred TCL1 leukemias in vivo. R788 treatment administered from days 4 to 25 after adoptive transfer significantly prevented the outgrowth of leukemias. Treatment with R788 significantly prolonged the survival of the animals. In B6/C3H mice, after 4 days of treatment animals receiving R788 showed a greater rise in the number of circulating malignant lymphocytes than controls. In B6/C3H F1 mice, treatment with R788 for 7 days blocked BCR signaling and inhibited leukemic cell survival and proliferation in vivo. In Eμ- TCL1 transgenic mouse model of CLL, R788 inhibited the growth of spontaneously developing TCL1 leukemias.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

- [1]. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma[J]. Blood, 2008, 111(4): 2230-2237.
- [2]. Suljagic M, Longo P G, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling[J]. Blood, 2010, 116(23): 4894-4905.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable

under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

